tbuckley/cabot-search huggingface dataset:
Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection
Authors: Nicolai Sidenius, Cornelis F. M. Sier, Henrik Ullum, Bente Klarlund Pedersen, Alessandro Cozzi Lepri, Francesco Blasi, Jesper Eugen-Olsen
Journal: Blood (2000)
No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes
Authors: Natasha C. Bergmann, Lærke S. Gasbjerg, Sebastian M. Heimbürger, Liva S.L. Krogh, Flemming Dela, Bolette Hartmann, Jens J. Holst, Lene Jessen, Mikkel B. Christensen, Tina Vilsbøll, Asger Lund, Filip K. Knop
Journal: Diabetes Care (2020)

Dual incretin receptor agonists in clinical development have shown reductions in body weight and hemoglobin A1c (HbA1c) in patients with type 2 diabetes, but the impact of glucose-dependent insulinotropic polypeptide (GIP) receptor activation remains unclear. Here, we evaluated the effects of high-dose exogenous GIP on energy intake, energy expenditure, plasma glucose, and glucose-regulating hormones in patients with type 2 diabetes treated with a long-acting glucagon-like peptide 1 receptor (GLP-1R) agonist.In a randomized, double-blind design, men with type 2 diabetes (n = 22, mean ± SEM HbA1c 6.8 ± 0.1% [51 ± 1.5 mmol/mol]) treated with metformin and long-acting GLP-1R agonists were subjected to two 5-h continuous infusions (separated by a washout period of ≥3 days): one with GIP (6 pmol/kg/min) and another with saline (placebo). After 60 min of infusion, a liquid mixed-meal test was performed, and after 270 min of infusion, an ad libitum meal was served for evaluation of energy intake (primary end point).Energy intake was similar during GIP and placebo infusion (648 ± 74 kcal vs. 594 ± 55 kcal, respectively; P = 0.480), as were appetite measures and energy expenditure. Plasma glucagon and glucose were higher during GIP infusion compared with placebo infusion (P = 0.026 and P = 0.017) as assessed by area under the curve.In patients with type 2 diabetes, GIP infusion on top of treatment with metformin and a long-acting GLP-1R agonist did not affect energy intake, appetite, or energy expenditure but increased plasma glucose compared with placebo. These results indicate no acute beneficial effects of combining GIP and GLP-1.
Survival Prediction in Ambulatory Stage III/ IV Non Small Cell Lung Cancer Patients Using the Palliative Performance Scale, Ecog and Lung Cancer Symptom Scale
Authors: R. Mohajer, S. Nathan, K. Wells, N. Kern, M. Batus, M. Fidler, P. Bonomi, S. O'Mahony
Journal: Annals of Oncology (2012)
Efficacy of psychosocial interventions for mental health outcomes in low-income and middle-income countries: an umbrella review
Authors: Corrado Barbui, Marianna Purgato, Jibril Abdulmalik, Ceren Acarturk, Julian Eaton, Chiara Gastaldon, Oye Gureje, Charlotte Hanlon, Mark Jordans, Crick Lund, Michela Nosè, Giovanni Ostuzzi, Davide Papola, Federico Tedeschi, Wietse Tol, Giulia Turrini, Vikram Patel, Graham Thornicroft
Journal: The Lancet Psychiatry (2020)
Phase III Trial of Everolimus in Advanced Pancreatic Neuroendocrine Tumors (RADIANT-3): Overall Population and Japanese Subgroup Analysis
Authors: T. Okusaka, T. Ito, M. Ikeda, H. Igarashi, C. Morizane, K. Nakachi, T. Tajima, A. Kasuga, Y. Fujita, J. Furuse
Journal: Annals of Oncology (2012)
Inter-country variability over time in the mortality of mechanically ventilated patients
Authors: Oscar Peñuelas, Alfonso Muriel, Victor Abraira, Fernando Frutos-Vivar, Jordi Mancebo, Konstantinos Raymondos, Bin Du, Arnaud W. Thille, Fernando Ríos, Marco González, Lorenzo del-Sorbo, Niall D. Ferguson, Maria del Carmen Marín, Bruno Valle Pinheiro, Marco Antonio Soares, Nicolas Nin, Salvatore M. Maggiore, Andrew Bersten, Pravin Amin, Nahit Cakar, Gee Young Suh, Fekri Abroug, Manuel Jibaja, Dimitros Matamis, Amine Ali Zeggwagh, Yuda Sutherasan, Antonio Anzueto, Andrés Esteban
Journal: Intensive Care Medicine (2020)
Tafamidis—A Pricey Therapy for a Not-So-Rare Condition
Authors: Jerry H. Gurwitz, Mathew S. Maurer
Journal: JAMA Cardiology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Heart regeneration with human pluripotent stem cells: Prospects and challenges
Authors: Yuqian Jiang, Xiaojun Lance Lian
Journal: Bioactive Materials (2020)

Cardiovascular disease, ranging from congenital heart disease to adult myocardial infarction, is the leading cause of death worldwide. In pursuit of reliable cardiovascular regenerative medicine, human pluripotent stem cells (hPSCs), including human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs), offer plenty of potential cell-based applications. HPSCs are capable of proliferating indefinitely in an undifferentiated state, and are also pluripotent, being able to differentiate into virtually any somatic cell types given specific stepwise cues, thus representing an unlimited source to generate functional cardiovascular cells for heart regeneration. Here we recapitulated current advances in developing efficient protocols to generate hPSC-derived cardiovascular cell lineages, including cardiomyocytes, endothelial cells, and epicardial cells. We also discussed applications of hPSC-derived cells in combination with compatible bioactive materials, promising trials of cell transplantation in animal models of myocardial infarction, and potential hurdles to bring us closer to the ultimate goal of cell-based heart repair.
The Clinical Significance of Pathologic Complete Response (PCR) after Neoadjuvant Chemotherapy and Treatment Strategy in HER2 and Hormonal Receptor Positive (HR+) Breast Cancer Patients
Authors: M. Tanioka, K. Hirokaga, K. Matsumoto, A. Kitao, T. Onoe, K. Tane, Y. Maekawa, S. Takao, S. Negoro
Journal: Annals of Oncology (2012)
PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
Authors: Minsuk Kwon, Chang Gon Kim, Hoyoung Lee, Hyunsoo Cho, Youngun Kim, Eung Chang Lee, Seong Jin Choi, Junsik Park, In-Ho Seo, Bjarne Bogen, Ik-Chan Song, Deog-Yeon Jo, Jin Seok Kim, Su-Hyung Park, Inhak Choi, Yoon Seok Choi, Eui-Cheol Shin
Journal: Clinical Cancer Research (2020)

Immune-checkpoint inhibitors have shown therapeutic efficacy in various malignant diseases. However, anti-programmed death (PD)-1 therapy has not shown clinical efficacy in multiple myeloma.Bone marrow (BM) mononuclear cells were obtained from 77 newly diagnosed multiple myeloma patients. We examined the expression of immune-checkpoint receptors in BM CD8+ T cells and their functional restoration by ex vivo treatment with anti-PD-1 and TGFβ inhibitors.We confirmed the upregulation of PD-1 and PD-L1 expression in CD8+ T cells and myeloma cells, respectively, from the BM of multiple myeloma patients. PD-1-expressing CD8+ T cells from the BM of multiple myeloma patients coexpressed other checkpoint inhibitory receptors and exhibited a terminally differentiated phenotype. These results were also observed in BM CD8+ T cells specific to myeloma antigens NY-ESO-1 and HM1.24. BM CD8+ T cells from multiple myeloma patients exhibited reduced proliferation and cytokine production upon T-cell receptor stimulation. However, anti-PD-1 did not increase the proliferation of BM CD8+ T cells from multiple myeloma patients, indicating that T-cell exhaustion in multiple myeloma is hardly reversed by PD-1 blockade alone. Intriguingly, anti-PD-1 significantly increased the proliferation of BM CD8+ T cells from multiple myeloma patients in the presence of inhibitors of TGFβ, which was overexpressed by myeloma cells.Our findings indicate that combined blockade of PD-1 and TGFβ may be useful for the treatment of multiple myeloma.
Recommendations Related to Genetic Testing for Breast Cancer
Authors: Paul F. Pinsky
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Viral genome search in myocardium of patients with fulminant myocarditis
Authors: Giacomo Veronese, Enrico Ammirati, Michela Brambatti, Marco Merlo, Manlio Cipriani, Luciano Potena, Paola Sormani, Tatsuo Aoki, Koichiro Sugimura, Akinori Sawamura, Takahiro Okumura, Sean Pinney, Kimberly Hong, Palak Shah, Oscar Ö. Braun, Caroline M. Van de Heyning, Santiago Montero, Duccio Petrella, Florent Huang, Matthieu Schmidt, Claudia Raineri, Anuradha Lala, Marisa Varrenti, Alberto Foà, Ornella Leone, Piero Gentile, Jessica Artico, Valentina Agostini, Rajiv Patel, Andrea Garascia, Emeline M. Van Craenenbroeck, Kaoru Hirose, Akihiro Isotani, Toyoaki Murohara, Yoh Arita, Alessandro Sionis, Enrico Fabris, Sherin Hashem, Victor Garcia‐Hernando, Fabrizio Oliva, Barry Greenberg, Hiroaki Shimokawa, Gianfranco Sinagra, Eric D. Adler, Maria Frigerio, Paolo G. Camici
Journal: European Journal of Heart Failure (2020)
The Galaxy Trial (NCT01348126): A Randomized IIB/III Study of Ganetespib (STA-9090) in Combination with Docetaxel Versus Docetaxel Alone as Second Line Therapy in Patients with Stage IIIB or IV NSCLC
Authors: S.S. Ramalingam, B. Zaric, G. Goss, C. Manegold, R. Rosell, V. Vukovic, I. El-Hariry, F. Teofilovici, A. Enke, D.A. Fennell
Journal: Annals of Oncology (2012)
Everolimus (EVE) Exposure in Patients (PTS) with Previously Treated advanced Gastric Cancer (AGC)
Authors: S. Al-Batran, N. Tebbutt, J. Xu, G. Luppi, H. Smith, C. Costantini, W. Cheung, S. Rizvi, T. Sahmoud, L. Shen
Journal: Annals of Oncology (2012)
Expanded Treatment Efficacy and Safety Study of Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma with Epirubicin/ Doxorubicin–Lipiodol Emulsion and Gelatin Particles: A Cooperative Study between Korea and Japan
Authors: M. Ikeda, Y. Arai, S.J. Park, Y. Takeuchi, H. Anai, J.K. Kim, Y. Inaba, T. Aramaki, S.H. Kwon, S. Yamamoto, T. Okusaka
Journal: Annals of Oncology (2012)
David Oliver: Staff hydration matters more than keeping up appearances
Authors: David Oliver
Journal: BMJ (2020)

Working as a clinician is physically and emotionally intense, often leaving little time to drink enough fluid, eat properly, or even have toilet breaks. A report by the Medical Protection Society on “breaking the burnout cycle” found that 40% of NHS doctors felt unable to take a break during the working day to eat and drink.1 Our nursing colleagues seem to experience the same pressure: a 2017 Royal College of Nursing report on safe and effective staffing found that 59% of nurses surveyed had not managed to take enough breaks during their last shift.2

We now have around one in 15 medical, and one in eight nursing, positions unfilled, with similar gaps across several clinical professions.3 We need to do all that we can to maintain staff …
The phosphatase PAC1 acts as a T cell suppressor and attenuates host antitumor immunity
Authors: None Dan Lu, Liang Liu, Yizhe Sun, Jia Song, Qi Yin, Guangze Zhang, Fang Qi, Zixi Hu, Zeliang Yang, Zhe Zhou, Ying Hu, Lianhai Zhang, Jiafu Ji, Xuyang Zhao, Yan Jin, Michael A. McNutt, Yuxin Yin
Journal: Nature Immunology (2020)
Superiority of Choi vs Recist Criteria in Evaluating Outcome of Advanced Soft Tissue Sarcoma (STS) Patients Treated with Sorafenib
Authors: R. De Sanctis, A.F. Bertuzzi, P. Magnoni, L. Giordano, M. Gasco, R. Lutman, A. Santoro
Journal: Annals of Oncology (2012)
O-0007 Exploratory Serum Biomarker Analyses from BO21129, a Phase II Study of Erlotinib in Second-Line Pancreatic Cancer: Potential Role of Amphiregulin?
Authors: Michel Ducreux, Irina Davidenko, David Propper, Giovanni Gerardo Cardellino, Avgust Garin, John Bridgewater, Minesh Jain, Limas Kupcinskas, Sufiya Safina, Alberto Fittipaldo, Walter Bordogna, Carina Hillenbach, Barbara Klughammer
Journal: Annals of Oncology (2012)
A Prospective, Feasibility Study of S-1 and Carboplatin for Patients with Pulmonary Fibrosis (PF) and Advanced Non-Small-Cell Lung Cancer (NSCLC)
Authors: T. Kato, O. Yamaguchi, M. Yoshida, H. Fukushima, A. Nakazawa, T. Oda, A. Takasa, T. Enomoto, T. Baba, H. Kitamura, T. Shinohara, R. Nishihira, S. Komatsu, E. Hagiwara, T. Ogura
Journal: Annals of Oncology (2012)
Phase II Study of Everolimus (E) in Refractory Germ Cell Tumors (GCTS)
Authors: M. Reckova, M. Mego, D. Svetlovska, V. Miskovska', J. Obertova, Z. Sycova-Mila, P. Palacka, J. Rajec, S. Liskova, J. Mardiak
Journal: Annals of Oncology (2012)
Connected real-life research, a pillar of P4 medicine
Authors: Nicolas Roche, Antonio Anzueto, Sinthia Bosnic Anticevich, Alan Kaplan, Marc Miravitlles, Dermot Ryan, Joan B. Soriano, Omar Usmani, Nikos Papadopoulos, G. Walter Canonica
Journal: European Respiratory Journal (2020)

<b>Assessment of m-Health tools needs to include high-quality real-life research studies. Reciprocally, real-life research can benefit highly from opportunities offered by connected devices.</b>http://bit.ly/2OK4Fqr
Multifunctional mesoporous black phosphorus-based nanosheet for enhanced tumor-targeted combined therapy with biodegradation-mediated metastasis inhibition
Authors: Leilei Chen, Min Qian, Huiling Jiang, Yiwei Zhou, Yilin Du, Yafeng Yang, Taotao Huo, Rongqin Huang, Yi Wang
Journal: Biomaterials (2020)
Reduced nucleotomy-induced intervertebral disc disruption through spontaneous spheroid formation by the Low Adhesive Scaffold Collagen (LASCol)
Authors: Yoshiki Takeoka, Takashi Yurube, Koichi Morimoto, Saori Kunii, Yutaro Kanda, Ryu Tsujimoto, Yohei Kawakami, Naomasa Fukase, Toshiyuki Takemori, Kaoru Omae, Yuji Kakiuchi, Shingo Miyazaki, Kenichiro Kakutani, Toru Takada, Kotaro Nishida, Masanori Fukushima, Ryosuke Kuroda
Journal: Biomaterials (2020)

Back pain is a global health problem with a high morbidity and socioeconomic burden. Intervertebral disc herniation and degeneration are its primary cause, further associated with neurological radiculopathy, myelopathy, and paralysis. The current surgical treatment is principally discectomy, resulting in the loss of spinal movement and shock absorption. Therefore, the development of disc regenerative therapies is essential. Here we show reduced disc damage by a new collagen type I-based scaffold through actinidain hydrolysis-Low Adhesive Scaffold Collagen (LASCol)-with a high 3D spheroid-forming capability, water-solubility, and biodegradability and low antigenicity. In human disc nucleus pulposus and annulus fibrosus cells surgically obtained, time-dependent spheroid formation with increased expression of phenotypic markers and matrix components was observed on LASCol but not atelocollagen (AC). In a rat tail nucleotomy model, LASCol-injected and AC-injected discs presented relatively similar radiographic and MRI damage control; however, LASCol, distinct from AC, decelerated histological disc disruption, showing collagen type I-comprising LASCol degradation, aggrecan-positive and collagen type II-positive endogenous cell migration, and M1-polarized and also M2-polarized macrophage infiltration. Reduced nucleotomy-induced disc disruption through spontaneous spheroid formation by LASCol warrants further investigations of whether it may be an effective treatment without stem cells and/or growth factors for intervertebral disc disease.
Following the community development of SIHUMIx – a new intestinal <i>in vitro</i> model for bioreactor use
Authors: Jannike Lea Krause, Stephanie Serena Schaepe, Katarina Fritz-Wallace, Beatrice Engelmann, Ulrike Rolle-Kampczyk, Sabine Kleinsteuber, Florian Schattenberg, Zishu Liu, Susann Mueller, Nico Jehmlich, Martin Von Bergen, Gunda Herberth
Journal: Gut Microbes (2020)

Diverse intestinal microbiota is frequently used in in vitro bioreactor models to study the effects of diet, chemical contaminations, or medication. However, the reproducible cultivation of fecal microbiota is challenging and the resultant communities behave highly dynamic. To approach the issue of reproducibility in in vitro models, we established an intestinal microbiota model community of reduced complexity, SIHUMIx, as a valuable model for in vitro use. The development of the SIHUMIx community was monitored over time with methods covering the cellular and the molecular level. We used microbial flow cytometry, intact protein profiling and terminal restriction fragment length polymorphism analysis to assess community structure. In parallel, we analyzed the functional level by targeted analysis of short-chain fatty acids and untargeted metabolomics. The stability properties constancy, resistance, and resilience were approached both on the structural and functional level of the community. We show that the SIHUMIx community is highly reproducible and constant since day 5 of cultivation. Furthermore, SIHUMIx has the ability to resist and recover from a pulsed perturbation, with changes in community structure recovered earlier than functional changes. Since community structure and function changed divergently, both levels need to be monitored at the same time to gain a full overview of the community development. All five methods are highly suitable to follow the community dynamics of SIHUMIx and indicated stability on day five. This makes SIHUMIx a suitable in vitro model to investigate the effects of e.g. medical, chemical, or dietary interventions.
The comparison of up-front autologous peripheral stem cell transplantation in first remission and long-lasting intensive chemotherapy protocols in highly aggressive non-Hodgkin’s lymphomas: Results of a retrospective analysis.
Authors: Mustafa Ozturk, Sukru Ozaydin, Basak Oyan, Murat Ozbalak, Fikret Arpaci, Semra Paydas, Selmin Ataergin, Burhan Ferhanoglu, Necmettin Kocak, Emel Gurkan, Ahmet Ozet, Ibrahim Barista
Journal: Journal of Clinical Oncology (2012)

6550 Background: Optimal therapy in adult patients with Burkitt’s and lymphoblastic lymphoma are still unknown. Despite long–lasting and intensive chemotherapy protocols, post-transplant relapse is common and the chemotherapy period is time consuming. Methods: In this retrospective study, the results of induction and consolidation chemotherapies followed-by high dose therapy (HDT) and autologous peripheral stem cell transplantation (APSCT) (n=21), which was given in a time period of 3 months were compared to long–lasting and intensive chemotherapy protocols (LICP) (n=39) in patients with Burkitt’s and Lymphoblastic lymphoma, without bone marrow or central nervous system involvement at presentation. Cyclophosphamide, vincristine, prednisolone, doxorubicin (Adriamycin) with or without L–asparaginase were given as induction chemotherapy, followed-by a consolidation chemotherapy with DHAP and up-front HDT. Results: More than 60% of patients in both groups were in the intermediate and high risk group according to International Prognostic Index. There was no significantly difference according to age, gender, bulky disease, stage, Burkitt’s and Lymphoblastic lymphoma ratio in both groups (p&gt;0,05). Median follow up was 32,3 months (min-max: 0-229 months). When HDT and LICP groups were compared: CR achieved in 76,3% and 82,1% of patients (p&gt;0,05); Median PFS was 10,4 months (min-max: 6,1-20,3) and 10,1 months (min-max: 6,3- 69,0) (p&gt;0,05); One year overall survival rate was 64,7% and 74,4% and five year overall survival rate was 50,1% and 56,7% (p&gt;0,05) respectively. Conclusions: The current study suggests that induction and consolidation chemotherapies followed by HDT and APSCT have similar CR, PFS and OS rates when compared to more time consuming LICP therapies. This provides a short period of treatment with a high rate of survival in adult patients with highly aggressive lymphomas in first remission.